Transbuccal Delivery of Chlorpheniramine Maleate from Mucoadhesive Buccal Patches

Sekhar, K. Chandra; Naidu, K. V. S.; Vishnu, Y Vamshi; Gannu, Ramesh; Veerabrahma, Kishan; Rao, Yi

doi:10.1080/10717540801952639

Cited by 27 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A representative transbuccal permeation profile is shown in Figure b. Drug flux, which is described as the quantity of drug that permeates per cross‐sectional area per minute, was also employed to further describe the permeation capacity of the CBZ‐loaded MCC. The MCC formulation displayed a trend whereby the flux changes per time was typified by an initial increase at 0.5 h [0.01 mg/(cm 2 min)] followed by a gradual decrease over time as shown in Figure c.…”

Section: Resultsmentioning

confidence: 99%

In Vivo and Ex Vivo Evaluation of a Multi-Particulate Composite Construct for Sustained Transbuccal Delivery of Carbamazepine

Adeleke

Choonara

Toit

et al. 2014

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

In Vivo and Ex Vivo Evaluation of a Multi-Particulate Composite Construct for Sustained Transbuccal Delivery of Carbamazepine

Adeleke

Choonara

Toit

et al. 2014

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…From the previous, it can be concluded that the mucoadhesive polymers retarded the release in the following order SCMC>HPMC100M>CbP934P. The retarding effect of SCMC and HPMC100M could be attributed to the fact that upon contact of both polymers with the dissolution medium, they undergo swelling forming a thick gel layer on the surface of the swollen patch which lead to an increase in the diffusional path length [40,41] in addition to the prevention of the matrix disintegration by retarding penetration of the dissolution medium into the patch [42]. Magdy et al found that montelukast released slowly from patches which were prepared from either SCMC or HPMC [14], Also, Mishra et al found that incorporation of HPMC retarded the release of simvastatin from Eudragit RS-100 patches [43].…”

Section: Ex-vivo Mucoadhesion Residence Timementioning

confidence: 99%

Sodium Cromoglycate Mucoadhesive Buccal Patches: Design, Fabrication, in Vitro and in Vivo Characterization

Sabry

2018

Int J App Pharm

View full text Add to dashboard Cite

Objective: The purpose of this study was to design and formulate mucoadhesive buccal patches of sodium cromoglycate (SCG) as an alternative way to overcome its poor oral absorption and short half-life.Methods: Mucoadhesive patches were prepared by solvent casting technique using cellulose acetate butyrate (CAB) alone or in combination with mucoadhesive polymers like SCMC (sodium carboxymethyl cellulose), HPMC 100M (hydroxyl propyl methyl cellulose) and Cbp934P (carbopol) in different concentrations. The successful patches were evaluated for thickness, weight variation, folding endurance, tensile strength, drug content, surface pH, moisture uptake, swelling percentage, mucoadhesion strength, residence time, in vitro release study, ex vivo permeation and in vivo pharmacokinetic studies.Results: The thickness of all prepared patches ranged from 0.210±0.006 to0.355±0.012, folding endurance was more than 300, weight variation did not exceed 0.179±0.015, tensile strength and % elongation ranged from 6.4±0.018 to 13.1±0.024, and from 30.4±0.88 to 53.4±0.78respectively. The swelling percentage after one hour was from 20.8±0.99 to 53.2±1.5. pH of all prepared patches did not exceed 6.8, the drug content was about 99 to 101%, moisture uptake did not exceed 10%. Mucoadhesion strength and residence time ranged from 17.2±0.14 to 51.2±0.26, and from 3.35±0.25 to 7.45±0.28 respectively. The cumulative release percentage of SCG was in the following descending order CAB>CAB with Cbp934P>CAB with HPMC>CAB with SCMC. The optimized patch (F9) decreased the Cmax and increased Tmax compared to the parenteral solution.Conclusion: It can be concluded that mucoadhesive buccal patch is a promising dosage form to prolong the release of SCG and enhance its poor oral bioavailability.

show abstract

“…Phosphate buffer pH 7.4 was placed over magnetic stirrer and the temperature was maintained at 37˚C. Samples of 1 ml were collected at predetermined time points from the receptor compartment and replaced with an equal volume of buffer 20,21 . Estimation of drug content in the sample was done by UV-Visible spectrophotometer.…”

Section: Ex Vivo Permeation Of Timolol Through Porcine Buccal Mucosa From Buccal Patchmentioning

confidence: 99%

Formulation and Evaluation of Timolol Buccal Patches

Shirisha¹,

Himabindhu²,

Behera³

et al. 2018

AJPTR

View full text Add to dashboard Cite

The present study is concerned with formulation and evaluation of mucoadhesive buccal patches containing antihypertensive drug i.e. Timolol to avoid the first pass effect and to improve its bioavailability with reduction in dosing frequency and also dose related side effects. The patches were prepared by solvent casting technique with varying concentration of HPMC E15 as polymer and propylene glycol as the plasticizer and evaluate their physicochemical properties, in vitro drug release, moisture absorption, surface pH, mechanical properties, in vitro bio adhesion, and ex vivo drug permeation through porcine buccal membranes from optimized buccal patch. The physicochemical interaction between timolol and polymer was investigated by Fourier transform infrared spectroscopy. Moisture absorption, surface pH, tensile strength, elongation at break, peak detachment force and work of adhesion values of the optimized formulation F4 were found to be 124±10.59%, pH 6.61±0.28, 3.89 kg/mm 2 , 14.16 mm 2 , 4.92±0.06N and 0.65±0.08mJ respectively. Formulation F4 showed 68.99 ±1.67% of the drug release in in vitro condition and follows zero order kinetics and drug release mechanism follows non-fickian diffusion. Ex vivo drug permeation through porcine buccal membrane was performed and 58.52±1.59% of the drug permeated in 6 hrs with flux 0.22 mg/h/cm 2 .The optimized formulation F4 with permeation enhancer tween 80 (1% v/w) showed drug release 64.47±1.63 % in 6 hrs with flux 0.33mg/h/cm 2 . FTIR studies showed no evidence of interaction between the drug and polymers. Drug release from the buccal patches follows desire controlled release phenomenon as required in mucoadhesive drug delivery.

show abstract

Transbuccal Delivery of Chlorpheniramine Maleate from Mucoadhesive Buccal Patches

Cited by 27 publications

References 22 publications

In Vivo and Ex Vivo Evaluation of a Multi-Particulate Composite Construct for Sustained Transbuccal Delivery of Carbamazepine

In Vivo and Ex Vivo Evaluation of a Multi-Particulate Composite Construct for Sustained Transbuccal Delivery of Carbamazepine

Sodium Cromoglycate Mucoadhesive Buccal Patches: Design, Fabrication, in Vitro and in Vivo Characterization

Formulation and Evaluation of Timolol Buccal Patches

Contact Info

Product

Resources

About